Elena Galli1, Yvan Guirette2, Damien Feneon2, Magalie Daudin2, Maxime Fournet2, Alain Leguerrier3, Erwan Flecher3, Philippe Mabo1, Erwan Donal4. 1. INSERM, UMR 1099, 35000 Rennes, France LTSI, Université de Rennes 1, 35000 Rennes, France Service de Cardiologie, CIC-IT 804, LISI INSERM U642, CHU Pontchaillou, 35000 Rennes, France. 2. Service de Cardiologie, CIC-IT 804, LISI INSERM U642, CHU Pontchaillou, 35000 Rennes, France. 3. Service de Chirurgie Cardio-Thoracique et Vasculaire, CHU Pontchaillou, 35000 Rennes, France. 4. INSERM, UMR 1099, 35000 Rennes, France LTSI, Université de Rennes 1, 35000 Rennes, France Service de Cardiologie, CIC-IT 804, LISI INSERM U642, CHU Pontchaillou, 35000 Rennes, France erwan.donal@chu-rennes.fr.
Abstract
AIMS: Systolic pulmonary artery pressure (sPAP) is a well-known outcome predictor in patients with valvular heart disease. Limited data are available regarding the evaluation of right ventricular (RV) performance, particularly in patients with aortic stenosis (AS). The aim of this study was to evaluate the prevalence, determinants, and prognostic significance of RV dysfunction in severe AS independently from the strategy of treatment chosen. METHODS AND RESULTS: Two hundred patients (mean age: 79.9 ± 8.8 years) with severe AS underwent two-dimensional and speckle tracking echocardiography for the evaluation of left ventricular (LV) and RV functions, aortic valve gradients, and sPAP. A tricuspid annular plane systolic excursion (TAPSE) ≤17 mm defined RV dysfunction. RV dysfunction was detected in 48 patients (24%). At multivariable regression analysis, LV global longitudinal strain (r = -0.29, P = 0.001), mean aortic gradient (r = 0.25, P = 0.002), and LV ejection fraction (r = 0.18, P = 0.02) were well correlated with TAPSE. After a median 16-month follow-up, cardiovascular death occurred in 17 patients. At multivariate Cox regression analysis, biventricular dysfunction (TAPSE ≤17 mm and LVEF ≤50%) emerged as the strongest predictor of prognosis (hazard ratio 4.08, 95% confidence interval 1.36-12.22; P = 0.012). CONCLUSIONS: RV dysfunction is common in AS patients, and this finding can likely be accounted for by the RV-LV interdependence. Given that biventricular function impairment was a strong predictor of mortality in our population, we suggest that RV dysfunction should be systematically looked for in AS patients. Published on behalf of the European Society of Cardiology. All rights reserved.
AIMS: Systolic pulmonary artery pressure (sPAP) is a well-known outcome predictor in patients with valvular heart disease. Limited data are available regarding the evaluation of right ventricular (RV) performance, particularly in patients with aortic stenosis (AS). The aim of this study was to evaluate the prevalence, determinants, and prognostic significance of RV dysfunction in severe AS independently from the strategy of treatment chosen. METHODS AND RESULTS: Two hundred patients (mean age: 79.9 ± 8.8 years) with severe AS underwent two-dimensional and speckle tracking echocardiography for the evaluation of left ventricular (LV) and RV functions, aortic valve gradients, and sPAP. A tricuspid annular plane systolic excursion (TAPSE) ≤17 mm defined RV dysfunction. RV dysfunction was detected in 48 patients (24%). At multivariable regression analysis, LV global longitudinal strain (r = -0.29, P = 0.001), mean aortic gradient (r = 0.25, P = 0.002), and LV ejection fraction (r = 0.18, P = 0.02) were well correlated with TAPSE. After a median 16-month follow-up, cardiovascular death occurred in 17 patients. At multivariate Cox regression analysis, biventricular dysfunction (TAPSE ≤17 mm and LVEF ≤50%) emerged as the strongest predictor of prognosis (hazard ratio 4.08, 95% confidence interval 1.36-12.22; P = 0.012). CONCLUSIONS:RV dysfunction is common in AS patients, and this finding can likely be accounted for by the RV-LV interdependence. Given that biventricular function impairment was a strong predictor of mortality in our population, we suggest that RV dysfunction should be systematically looked for in AS patients. Published on behalf of the European Society of Cardiology. All rights reserved.
Authors: K Balderas-Muñoz; H Rodríguez-Zanella; J F Fritche-Salazar; N Ávila-Vanzzini; L E Juárez Orozco; J A Arias-Godínez; O Calvillo-Argüelles; S Rivera-Peralta; J C Sauza-Sosa; M E Ruiz-Esparza; E Bucio-Reta; A Rómero; N Espinola-Zavaleta; B Domínguez-Mendez; M Gaxiola-Macias; M A Martínez-Ríos Journal: Int J Cardiovasc Imaging Date: 2017-05-09 Impact factor: 2.357
Authors: LaTonya J Hickson; Sara M Negrotto; Macaulay Onuigbo; Christopher G Scott; Andrew D Rule; Suzanne M Norby; Robert C Albright; Edward T Casey; John J Dillon; Patricia A Pellikka; Sorin V Pislaru; Patricia J M Best; Hector R Villarraga; Grace Lin; Amy W Williams; Vuyisile T Nkomo Journal: J Am Coll Cardiol Date: 2016-03-15 Impact factor: 24.094
Authors: Hongju Zhang; Edward A El-Am; Jeremy J Thaden; Sorin V Pislaru; Christopher G Scott; Chayakrit Krittanawong; Anwar A Chahal; Thomas J Breen; Mackram F Eleid; Rowlens M Melduni; Kevin L Greason; Robert B McCully; Maurice Enriquez-Sarano; Jae K Oh; Patricia A Pellikka; Vuyisile T Nkomo Journal: Heart Date: 2019-08-22 Impact factor: 5.994